胰腺癌术前治疗病理主要缓解的影像学与血清学预测因素
该研究回顾性分析2010至2018年间290例接受术前化疗和/或放化疗后行胰腺切除术的局限性胰腺导管腺癌(PDAC)患者,以病理主要缓解(pMR,存活癌细胞<5%)为终点,发现治疗后低CA 19-9水平、RECIST部分缓解及肿瘤体积缩小与pMR独立相关(P<0.01)。
要点
- 治疗后CA 19-9低水平与pMR独立相关(P<0.01)
- RECIST部分缓解与pMR独立相关(P<0.01)
- 肿瘤体积缩小与pMR独立相关(P<0.01)
核心结论
- 治疗后低CA 19-9水平、RECIST部分缓解和肿瘤体积缩小是pMR的独立预测因素。
研究设计与样本
- 回顾性队列研究,纳入2010年1月至2018年12月接受术前化疗和/或放化疗后行胰腺切除术的290例局限性PDAC患者。
主要发现
- 290例中28例(10%)发生pMR,其中9例(3.1%)为病理完全缓解。
- 多因素logistic回归显示治疗后低CA 19-9水平、RECIST部分缓解和肿瘤体积缩小与pMR独立相关(P<0.01)。
关键数值与推荐
- pMR定义为手术标本组织病理学分析中存活癌细胞<5%。
- 术前治疗方式:化疗36例(12%)、放化疗87例(30%)、两者兼有167例(58%)。
临床怎么用
- 治疗后CA 19-9水平、RECIST缓解和肿瘤体积变化可用于辅助判断PDAC患者术前治疗的病理主要缓解情况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We sought to identify potential radiologic and serologic markers of pancreatic tumor response to therapy, using pathologic major response (pMR) as the objective endpoint. BACKGROUND: We previously demonstrated that a pMR to preoperative therapy, defined as detection of <5% viable cancer cells in the surgical specimen on histopathological analysis, is an important prognostic factor for patients with pancreatic ductal adenocarcinoma (PDAC). METHODS: Pretreatment and posttreatment computed tomography scans of consecutive patients who received preoperative chemotherapy and/or (chemo)radiation before pancreatectomy for PDAC between January 2010 and December 2018 were rereviewed. Response per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, other radiographic changes in tumor size and anatomic extent, and posttreatment CA 19-9 levels were compared between patients who did and did not have a pMR on final histopathologic analysis of their surgical specimens. RESULTS: A total of 290 patients with localized PDAC underwent pancreatectomy between 2010 and 2018 after receiving preoperative chemotherapy (n = 36; 12%), (chemo)radiation (n = 87; 30%), or both (n = 167; 58%). Among them, 28 (10%) experienced pMR, including 9 (3.1%) who experienced pathologic complete response. On multivariable logistic regression, low posttreatment CA 19-9 level, RECIST partial response, and reduction in tumor volume were confirmed to be independently associated with pMR (P < 0.01). CONCLUSIONS: We identified serologic and radiographic indicators of pMR that could help inform the delivery of preoperative therapy to patients with PDAC.
引用
- Perri G, Prakash L, Wang H, et al. Radiographic and Serologic Predictors of Pathologic Major Response to Preoperative Therapy for Pancreatic Cancer. Ann Surg. 2021. PMID: 31274655. doi:10.1097/SLA.0000000000003442
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。